Arcutis Insider Matsuda Sells 3,674 Shares, Maintaining Steady 10‑b‑5‑1 Plan
Arcutis Biotherapeutics insider Matsuda Masaru sells 3,674 shares at $25 each—steady 10‑b‑5‑1 trades signal routine liquidity, not distress.
3 minutes to read
ARCUTIS BIOTHERAPEUTICS INC
Arcutis Insider Buying Signals Confidence as Biotech Rally Fuels Market‑Access Hope
Arcutis insiders buy shares amid 2026 biotech rally, signaling confidence in its immune‑mediated pipeline and upcoming payer deals.
4 minutes to read
Arcutis Insider Sale: What Masaru Matsuda’s 9,989‑Share Trade Signals for Investors
Arcutis Biotherapeutics insider sale shows routine liquidity planning, not a warning. Explore the company’s robust pipeline, strong fundamentals, and market outlook for informed investing.
5 minutes to read